Fri May 16 15:33:33 UTC 2025: **Summary:**
Novo Nordisk is replacing CEO Lars Fruergaard Jorgensen amidst concerns about losing its dominance in the obesity drug market to competitors like Eli Lilly. The decision follows a recent sales and profit forecast cut, the first since Wegovy’s launch. While Jorgensen oversaw a period of massive growth fueled by Wegovy and Ozempic, the company’s stock has plummeted due to increased competition and underwhelming new drug pipeline. Analysts express surprise at the move, questioning the timing given Novo Nordisk’s previous success under Jorgensen’s leadership. The news has impacted Novo Nordisk’s share price, while competitor Eli Lilly’s stock has risen.
**News Article:**
**Novo Nordisk Ousts CEO as Weight-Loss Drug Competition Heats Up**
COPENHAGEN – Novo Nordisk, the pharmaceutical giant behind the popular weight-loss drug Wegovy, announced Friday that it is replacing CEO Lars Fruergaard Jorgensen. The move comes as the company faces increasing competition in the lucrative obesity drug market, primarily from U.S.-based Eli Lilly.
The decision follows a recent downward revision of Novo Nordisk’s sales and profit forecast, the first such adjustment since Wegovy’s launch four years ago. While Jorgensen had predicted a return to growth in its biggest market in the second half of this year, the change at the top suggests deeper concerns about the company’s strategy and execution.
“The changes are made in light of the recent market challenges Novo Nordisk has been facing, and the development of the company’s share price since mid-2024,” the company said in a statement.
Under Jorgensen’s eight-year tenure, Novo Nordisk became a global leader in weight-loss treatments, with Wegovy and Ozempic driving unprecedented sales. However, the company’s stock has taken a significant hit since reaching record highs last June, losing roughly half its market value. Eli Lilly’s Zepbound has begun to surpass Wegovy in U.S. prescriptions, adding to the pressure on Novo Nordisk.
Analysts have expressed surprise at the CEO change. “He was leading the company for eight years and was, in my opinion, extremely successful,” Lukas Leu, a portfolio manager at Bellevue Asset Management, told Reuters.
The news sent Novo Nordisk’s shares down. Meanwhile, Eli Lilly’s shares saw a boost, indicating investors believe the shift at Novo Nordisk could further benefit its rival. Former CEO of Novo Nordisk for 16 years and current chair of the Novo Nordisk Foundation, Lars Rebien Sorensen, will join the board as an observer. Jorgensen will remain in his role until a successor is found. The company is controlled by the Novo Nordisk Foundation, which owns a significant stake in the company.
First Piper 